Enalaprilat is commonly used to address hypertension when oral therapy is not practical. This medication is applied across therapeutic domains where additional symptomatic support is needed for acute blood pressure control.

The medication is relevant in clinical settings that involve symptoms related to systemic imbalance, and is used to ease the symptoms that create noticeable physiological strain. It is commonly used for managing conditions characterized by periods of heightened symptoms, relevant to managing symptoms associated with acute or episodic changes.

In scenarios where patients are unable to take oral medication (e.g., due to critical care constraints or altered consciousness), this treatment supports the patient during difficult episodes by easing distress and contributes to improved comfort.

“This treatment supports the patient during difficult episodes by easing distress and contributes to improved comfort.”

Regulatory References

1. U.S. National Institutes of Health (NIH) DailyMed

Enalaprilat Injection is an Angiotensin-Converting Enzyme (ACE) Inhibitor primarily allowed for use in adults and children age 1 month to 16 years for the management of hypertension. Eligibility is strictly governed by regulatory-defined contraindications and population-specific restrictions.

Who Cannot Use Enalaprilat (Contraindicated)

Populations Requiring Caution or Restriction

• Infants and Neonates: Use is not recommended in children younger than one month of age.
• Severe Renal Impairment: Use requires caution and adjustment in patients with a Glomerular Filtration Rate (GFR) leq 30 mL/min. Use is not recommended in children with severe renal impairment.
• Other Conditions: Patients who are severely volume-depleted (e.g., from dialysis or intensive diuresis) or who have certain collagen vascular diseases require special caution.

Interactions with other medicines and products

This section describes officially documented interaction patterns for Enalaprilat, based strictly on government regulatory labeling, concerning co-administration with other substances.

Contraindicated and Restricted Combinations

Pharmacodynamic and Exposure Interactions

Co-administration with other medicines may result in pharmacodynamic changes or altered drug exposure:

• Potassium-Sparing Diuretics (e.g., Spironolactone) and Potassium Supplements/Salt Substitutes can lead to an increased risk of hyperkalemia (elevated serum potassium).
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may result in the deterioration of renal function, particularly in elderly or volume-depleted patients.
• Lithium co-administration may increase serum Lithium levels, necessitating frequent monitoring of Lithium concentration due to reduced clearance.
• Agents known to increase angioedema risk, such as mTOR Inhibitors (e.g., Sirolimus) or DPP-IV Inhibitors, should be used cautiously as they further elevate the risk of angioedema. The overall interaction profile mandates strict adherence to procedural constraints and monitoring protocols defined in official prescribing information.

Enalaprilat functions as a competitive inhibitor of angiotensin-converting enzyme (ACE), a metallopeptidase localized primarily to the luminal surface of endothelial cells, particularly within the pulmonary circulation. The drug, which is the active dicarboxylate metabolite of the prodrug enalapril, binds to the zinc-containing active site of ACE. This interaction prevents ACE from catalyzing the cleavage of the C-terminal dipeptide from angiotensin I (Ang I). This molecular event consequently reduces the formation of the potent vasoconstrictor and aldosterone-releasing peptide, angiotensin II (Ang II).

Simultaneously, the inhibition of ACE reduces the enzymatic degradation of circulating bradykinin, an endogenous peptide that mediates vasodilation. The resulting accumulation of bradykinin and the reduction in Ang II concentration induce vasodilation in both arterial and venous vascular beds. This system-level physiological modulation involves a decrease in systemic vascular resistance and a concurrent reduction in the renal tubular reabsorption of sodium and water mediated by reduced aldosterone signaling.

How to Use Enalaprilat

Enalaprilat is used based on protocols governing its administration in acute care settings. As a potent, active metabolite, it is supplied exclusively as a sterile solution for intravenous (IV) administration. This parenteral route is used because the compound is poorly absorbed when taken orally.

Administration Scope

Procedural Structure and Course Duration

Each injection is administered slowly, over a period of at least five minutes. The intravenous solution may be given undiluted or diluted in specific compatible fluids, such as 0.9% sodium chloride or 5% dextrose, up to mathbf50 mL. This acute IV treatment is generally short-term, typically employed until the patient is stabilized and can be transitioned to oral therapy.

Transitioning from the injection to the oral prodrug, Enalapril maleate, is a core procedural step. For instance, a patient receiving the standard mathbf1.25 mg IV dose typically converts to mathbf5 mg of the oral tablet once daily; a patient on the reduced mathbf0.625 mg IV dose converts to mathbf2.5 mg oral once daily.

Overview of Clinical Research

Enalaprilat is the active metabolite of the prodrug enalapril, belonging to the class of Angiotensin-Converting Enzyme (ACE) inhibitors. The intravenous formulation of Enalaprilat is used in clinical settings for the management of high blood pressure (hypertension) when oral therapy is not feasible. The primary focus of clinical research has been on its rapid effects on blood pressure and its use in treating heart failure.

Findings on Blood Pressure and Hemodynamics

Studies have consistently demonstrated that intravenous administration of Enalaprilat is associated with a reduction in both systolic and diastolic blood pressure. The onset of this action is typically observed within 15 minutes of administration, with the maximum observed effect usually occurring between one and four hours.

Research has explored the use of bolus intravenous Enalaprilat in patients with acute hypertensive heart failure (AHF). One retrospective study examining patients presenting with acutely high blood pressure and heart failure symptoms observed a substantial reduction in systolic blood pressure within three hours following administration. No significant immediate deterioration of kidney function (as measured by serum creatinine) was noted in this cohort.

Clinical and Pharmacokinetic Metrics

Ongoing clinical trials continue to investigate the potential of Enalaprilat and its parent drug, Enalapril, in areas such as diabetic nephropathy and different forms of congestive heart failure.

The storage and disposal of Enalaprilat Injection, USP, are strictly defined by regulatory guidelines to maintain potency and sterility.

Official Storage Conditions

Disposal

Disposal of unused or expired product must be performed according to local regulations. Enalaprilat is not on the FDA's list of medicines recommended for flushing down the toilet.